SNAP-8 is an octapeptide marketed as a cosmetic alternative to botulinum toxin, relaxing facial expression muscles to reduce expression lines and wrinkles; the only community use cases on record center on those two goals. Reported doses span 2 mg to 30 mg daily, with 10 mg the most commonly cited figure, though most accounts don't specify timing or a cycling pattern. There are no approved indications, and the evidence base doesn't extend beyond preclinical mechanistic work — all human use is off-label or compounded.
Data last updated
Measured on 4 of 6 axes
Evidence shape
SNAP-8 sits at the animal-only tier: the mapped evidence covers preclinical and mechanistic research, with no human published studies on record. There are no registered clinical trials — not completed, not ongoing, not terminated — leaving a single indication studied only in laboratory models. That absence is the signal: SNAP-8 has not crossed into human investigation at any scale.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 10 out-of-stock offers not shown
How SNAP-8 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Across 8 community reports, doses cluster around 10 mg subQ, with a wide spread from 2 mg to 30 mg. Most sources don't specify frequency; of the two that do, one reports 2–2.5 mg daily and another 4 mg weekly.